Chardan Capital Has Negative Outlook of COYA FY2025 Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Investment analysts at Chardan Capital lowered their FY2025 earnings per share (EPS) estimates for Coya Therapeutics in a note issued to investors on Wednesday, May 14th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.57) per share for the year, down from their previous estimate of ($1.03). Chardan Capital has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.44). The company had revenue of $257.88 million for the quarter, compared to the consensus estimate of $2.63 million.

Separately, D. Boral Capital reissued a "buy" rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Tuesday, April 22nd.

Coya Therapeutics Stock Up 1.0%

Shares of NASDAQ:COYA opened at $5.93 on Monday. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The stock has a market capitalization of $99.18 million, a PE ratio of -9.12 and a beta of 0.49. The firm's 50 day moving average price is $6.05 and its 200-day moving average price is $6.17.

Institutional Trading of Coya Therapeutics

A number of institutional investors have recently bought and sold shares of COYA. Tower Research Capital LLC TRC increased its position in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock valued at $30,000 after acquiring an additional 4,777 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new position in Coya Therapeutics during the 1st quarter valued at about $65,000. XTX Topco Ltd bought a new position in Coya Therapeutics during the 4th quarter valued at about $59,000. Jane Street Group LLC purchased a new stake in Coya Therapeutics in the 4th quarter worth about $74,000. Finally, Northern Trust Corp lifted its stake in Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.